Effect of rosuvastatin in reducing free radical damage in patients with diabetes
Phase 4
Completed
- Conditions
- Health Condition 1: null- Type 2 Diabetes Mellitus patients
- Registration Number
- CTRI/2018/07/014771
- Lead Sponsor
- Sri Venkateswara Institute of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 24
Inclusion Criteria
Patients with T2DM aged between 30-60 years as per the revised ADA
(American Diabetic Association) criteria i.e.,(12)
i) Fasting plasma glucose =126mg/dL (7.0 mmol/L)
ii) 2 hour plasma glucose =200mg/dL (11.1 mmol/L)
iii) Glycosylated hemoglobin (HbA1c) >6.5% (48 mmol/mol)
Exclusion Criteria
Patients with other forms of diabetes (T1DM, Gestational diabetes mellitus)
Those on insulin therapy
Thyroid disorders not on treatment
Those on pioglitazone
Liver and kidney diseases
Other inflammatory diseases
Acute illness
Malignancy
Alcoholics
Current smoking
Those on cholesterol lowering drugs
Individuals who are not willing to participate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study the effect of rosuvastatin on oxidant and antioxidant status in patients with type 2 diabetes mellitus. <br/ ><br> <br/ ><br>Timepoint: baseline and after 12 weeks
- Secondary Outcome Measures
Name Time Method Determine the lipid lowering capacity of rosuvastatin by assessment of lipid profile in patients with T2DM before and after 12 weeks of Rosuvastatin treatmentTimepoint: Baseline and after 12 weeks